Edition:
United Kingdom

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

17.90USD
19 Jan 2018
Change (% chg)

$0.09 (+0.51%)
Prev Close
$17.81
Open
$17.73
Day's High
$18.39
Day's Low
$17.28
Volume
86,145
Avg. Vol
125,426
52-wk High
$31.23
52-wk Low
$8.10

Latest Key Developments (Source: Significant Developments)

Akcea Initiates Phase 2b Study Of Hypertriglyceridemia And Established Heart Disease Treatment
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Akcea Therapeutics Inc ::AKCEA INITIATES PHASE 2B STUDY OF AKCEA-APOCIII-LRX IN PATIENTS WITH HYPERTRIGLYCERIDEMIA AND ESTABLISHED CARDIOVASCULAR DISEASE.AKCEA THERAPEUTICS INC - ‍ ANTICIPATES REPORTING TOP-LINE DATA FROM PHASE 2B OF AKCEA-APOCIII-L(RX)​ STUDY IN 2019.  Full Article

Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Akcea Therapeutics Inc :Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS.Akcea Therapeutics Inc - ‍in U.S., Food And Drug Administration assigned a prescription drug user fee act goal date of August 30, 2018​.Akcea Therapeutics Inc - marketing applications for Volanesorsen been accepted for review in U.S., EU & Canada for treatment of patients with FCS.  Full Article

Akcea initiates AKCEA-ANGPTL3-LRx Phase 2 program in patients with rare hyperlipidemias
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Akcea Therapeutics Inc :Akcea initiates AKCEA-ANGPTL3-LRx Phase 2 program in patients with rare hyperlipidemias.Akcea Therapeutics Inc - ‍AKCEA-ANGPTl3-L(Rx )is designed to reduce production of angiopoietin-like 3, or ANGPTL3​.  Full Article

Akcea Therapeutics Q3 loss per share $0.27
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Akcea Therapeutics Inc :Q3 loss per share $0.27.Akcea Therapeutics Inc qtrly ‍revenue $13.4 million​.Q3 earnings per share view $-0.19, revenue view $11.9 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Akcea Initiates Phase 2b Study Of Hypertriglyceridemia And Established Heart Disease Treatment

* AKCEA INITIATES PHASE 2B STUDY OF AKCEA-APOCIII-LRX IN PATIENTS WITH HYPERTRIGLYCERIDEMIA AND ESTABLISHED CARDIOVASCULAR DISEASE